Comparison of Efficacy and Safety of Aripiprazole and Risperidone in the Treatment of Behavioral and Psychological Symptoms of Dementia

Abstract:

Objective To assess the effect and safety of aripiprazole and risperidone in the treatment of Behavioral and psychological symptoms of dementia (BPSD). Methods 68 dementia were randomly divided into aripiprazole group (n=34) and risperidone group (n=34) with a course of 8 weeks. BEHAVE-AD and TESS were used to evaluate the efficacy and adverse effect respectively before and at the ends of 8 weeks treatment. Their levels of blood glucose, total cholesterol (TC), triglyceride (TG), high Density lipoprotein–cholesterol (HDL), low density lipoprotein–cholesterol (LDL) and weight were measured at baseline and after 8 weeks. Results After 8 weeks treatment, the scores of BEHAVE-AD of patients in both groups significantly reduced (P<0.001),but there were no significantly difference between the two groups (P>0.05);there were few side effects in the two groups, but the weight gains, total cholesterol and LDL in risperidone group were higher effect than before treatment. The aripiprazole group had no significantly change. Conclusion The results suggest that aripiprazole is as effective and safety as risperidone for the treatment of BPSD, but aripiprazole has fewer effects on blood glucose, lipids and weight than risperidone.

• Periodical: Applied Mechanics and Materials (Volume 595)
• Pages: 258-262
• DOI: https://doi.org/10.4028/www.scientific.net/AMM.595.258
• Online since: July 2014
• Authors: Ke Yong Luo*, Hua Bin Fu
• Keywords: Aripiprazole, Behavioral Symptoms, Dementia, Efficacy, Psychological Symptoms, Risperidone, Safety

References

[1] J.P. Jia: Chinese Diagnosis and Treatment Guideline for Dementia and Cognitive disorder[M]. edited by People's Medical Publishing House, Beijing 2010, 1-169.

[2] Y.L. Jing, Z. A Zhang and D.M. Wang: Observation of Curative Effect for Treatment of Alzheimer's Disease Symptom by use of Olanzapine. edited by Sichuan Mental Health[J], 2009, 22(3): 176-177.

[3] W.F. Zhen: Research Progress of Treatment of Alzheimer Disease Patient with Concomitant Dementia and Psychotic symptom by use of Atypical Antipsychotic Drugs. edited by Foreign Medical Sciences(Geriatrics)[J], 2009, 30(5): 196-199.

[4] K.D. Jiang: Psychopharmacology[M]. People's Medical Publishing House, Beijing 2007. 340-345.

[5] X.L. Wang, J.D. Liu and L. Chen et al: Control Study on Behavioral and Psychological Symptoms of Senile Dementia. edited by China Journal of Health Psychology[J], 2010, 18(1): 1-2.

[6] R.R. Li, J.F. Gao and Q. Hou: Clinical Observation of Treatment of Behavioral and Psychological Symptoms of Senile Dementia by use of Quetiapine. edited by Shanghai Archives of Psychiatry[J], 2009, 21(6): 355-257.

[7] D.S. Yu: Pathophysiological Effect of Monoamine. edited by Journal of Clinical Psychosomatic Diseases[J], 2006, 12(1): 75-77.

[8] J.P. Dai, Z.H. Zhao, G.X. Liu et al: Comparison of Curative Effect and Safety of Aripiprazole and Quetiapine in Treatment of Schizophrenia. edited by Chinese Journal of Behavioral Medical Science[J], 2005, 14(8): 712-714.

[9] Streim JE, Porsteinsson AP, Breder CD. A randomized double-blind Placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease[J]. Am J Geriatr Psychiatry, 2008, 16(7): 537-50.

DOI: 10.1097/jgp.0b013e318165db77

[10] M.P. Wang: Influence of New Antipsychotic Drug Aripiprazole on Glycometabolism and the Relationship with Glycosylated Hemoglobin edited by Hebei Medical Journal[J], 2009, 31(14): 1752-1753.